EMA
withdrawal
· 2012-04-20
European Medicines Agency maintains recommendation not to grant a marketing authorisation for Glybera
Summary
The European Medicines Agency maintains its recommendation not to grant marketing authorisation for Glybera (alipogene mimutran) for lipoprotein lipase deficien…
Upgrade for the full analysis, importance score, and drug timeline.